Condition: Primary Central Nervous System Lymphoma · Sponsor: Providence Health & Services
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
This description comes directly from the study's public registry record.
Tiffany Gervasi-Follmar · 503-216-1023 · tiffany.gervasi-follmar@providence.org
Holly Rittenberry · 503-216-1034 · Holly.Rittenberry@providence.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Not Yet Recruiting |
| Providence Health & Services; Providence Neurological Specialties | Portland, Oregon, United States | Recruiting |
| Pennsylvania State University | Hershey, Pennsylvania, United States | Recruiting |
| University of Vermont | Burlington, Vermont, United States | Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
| Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06175000